Cold Sores

Author(s):  
Michael Wilson ◽  
Philippa J. K. Wilson
Keyword(s):  
1997 ◽  
Vol 22 (10) ◽  
pp. 126
Author(s):  
S L Spruance ◽  
T L Rea ◽  
C Thoming
Keyword(s):  

2003 ◽  
Vol 47 (3) ◽  
pp. 1072-1080 ◽  
Author(s):  
Spotswood L. Spruance ◽  
Terry M. Jones ◽  
Mark M. Blatter ◽  
Mauricio Vargas-Cortes ◽  
Judy Barber ◽  
...  

ABSTRACT Oral valacyclovir is better absorbed than oral acyclovir, increasing acyclovir bioavailability three- to fivefold. This provides the opportunity to explore whether high systemic acyclovir concentrations are effective in the treatment of cold sores (herpes labialis). Two randomized, double-blind, placebo-controlled studies were conducted. Subjects were provided with 2 g of valacyclovir twice daily for 1 day (1-day treatment), 2 g of valacyclovir twice daily for 1 day and then 1 g of valacyclovir twice daily for 1 day (2-day treatment), or a matching placebo and instructed to initiate treatment upon the first symptoms of a cold sore. In study 1, the median duration of the episode (primary endpoint) was reduced by 1.0 day (P = 0.001) with 1-day treatment and 0.5 days (P = 0.009) with 2-day treatment compared to placebo. Similarly, the mean duration of the episode was statistically significantly reduced by 1.1 days with 1-day treatment and 0.7 days with 2-day treatment compared to placebo. The proportion of subjects in whom cold sore lesion development was prevented and/or blocked was increased by 6.4% (P = 0.096) with 1-day treatment and 8.5% (P = 0.061) with 2-day treatment compared to placebo. The time to lesion healing and time to cessation of pain and/or discomfort were statistically significantly reduced with valacyclovir compared to placebo. In study 2, results similar to those in study 1 were obtained. AEs were similar across treatment groups. These studies provide evidence supporting a simple, 1-day valacyclovir treatment regimen for cold sores that is safe and effective. The 1-day valacyclovir regimen offers patients a unique and convenient dosing alternative compared to available topical therapies.


InPharma ◽  
1983 ◽  
Vol 410 (1) ◽  
pp. 13-13 ◽  
Keyword(s):  

The Lancet ◽  
1978 ◽  
Vol 311 (8055) ◽  
pp. 103 ◽  
Author(s):  
Sanford Danziger
Keyword(s):  

2021 ◽  
Vol 2021 (9) ◽  
Author(s):  
Chuanfang Lee ◽  
Ching-Chi Chi ◽  
Shu-Ching Hsieh ◽  
Charn-Jung Chang ◽  
Finola M Delamere ◽  
...  
Keyword(s):  

CHEST Journal ◽  
2019 ◽  
Vol 156 (4) ◽  
pp. A2050 ◽  
Author(s):  
ayesha shaik ◽  
Varun Tandon ◽  
Ayesha Azmeen
Keyword(s):  

2003 ◽  
Vol 13 (6) ◽  
pp. 35-36
Author(s):  
Alison Blenkinsopp ◽  
Paul Paxton ◽  
John Blenkinsopp ◽  
Sandy Reid
Keyword(s):  

BMJ Open ◽  
2017 ◽  
Vol 7 (8) ◽  
pp. e017766 ◽  
Author(s):  
Alex Semprini ◽  
Joseph Singer ◽  
Nicholas Shortt ◽  
Irene Braithwaite ◽  
Richard Beasley

IntroductionWorldwide, about 90% of people are infected with the herpes simplex virus, 30% of whom will experience recurrent herpes simplex labialis, commonly referred to as ‘cold sores’, which can last up to 10 days. The most common treatment is aciclovir cream which reduces healing time by just half a day compared with no specific treatment. This is a protocol for a randomised controlled trial (RCT) to determine the efficacy of medical grade kanuka honey-based topical treatment (Honevo) in reducing the healing time and pain of cold sores, compared with topical aciclovir treatment (Viraban).Methods and analysisThis open-label, parallel-group, active comparator superiority RCT will compare the efficacy of medical grade kanuka honey with 5% aciclovir cream in the treatment of cold sores in the setting of a pharmacy research network of 60 sites throughout New Zealand. Adults presenting with a cold sore (N=950) will be randomised by pharmacy-based investigators. The pharmacy-based investigators will dispense the investigational product to randomised participants and both study groups apply the treatment five times daily until their skin returns to normal or for 14 days, whichever occurs first. In response to a daily SMS message, participants complete an assessment of their cold sore healing, with reference to a visual guide, and transmit it to the investigators by a smartphone eDiary in real time. The primary outcome variable is time (in days) from randomisation to return to normal skin. Secondary endpoints include total healing time stratified by stage of the lesion at onset of treatment, highest pain severity and time to pain resolution.Ethics and disseminationNew Zealand Ethics Registration 15/NTB/93. Results will be published in a peer-reviewed medical journal, presented at academic meetings and reported to participants.Trial registration numberAustralia New Zealand Clinical Trials Registry: ACTRN12615000648527, pre-results.SCOTT Registration: 15/SCOTT/14Protocol version4.0 (12 June 2017)


Sign in / Sign up

Export Citation Format

Share Document